Loomis, Sayles & Company
TARS icon

Loomis, Sayles & Company’s Tarsus Pharmaceuticals TARS Stock Holding History

Loomis, Sayles & Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.6M Sell
407,836
-34,037
-8% -$2.38M 0.04% 175
2025
Q4 		$36.2M Buy
441,873
+51,972
+13% +$3.88M 0.04% 151
2025
Q3 		$23.2M Buy
+389,901
New +$19.2M 0.03% 216

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company's TARS Position: Q1 2026 in Review

Loomis, Sayles & Company reduced its Tarsus Pharmaceuticals (TARS) stake by 7.7% in Q1 2026, selling an estimated $2.38M and leaving 407,836 shares worth $28.6M. The position accounts for 0.04% of the portfolio, ranked #175.

Loomis, Sayles & Company first reported a position in TARS in Q3 2025 and has held it in 3 quarters since. The position peaked at $36.2M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Loomis, Sayles & Company held 407,836 shares of Tarsus Pharmaceuticals worth $28.6M as of Q1 2026.
  • Loomis, Sayles & Company sold 34,037 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $2.38M.
  • Tarsus Pharmaceuticals made up 0.04% of Loomis, Sayles & Company's portfolio in Q1 2026, its #175 holding.
  • Loomis, Sayles & Company first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Loomis, Sayles & Company's Tarsus Pharmaceuticals position peaked at $36.2M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.